| 241.65 -0.42 (-0.17%) | 12-08 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 285.47  |
1-year : | 333.42 |
| Resists | First : | 244.41 |
Second : | 285.47 |
| Pivot price | 235.21 |
|||
| Supports | First : | 228.78 |
Second : | 219.11 |
| MAs | MA(5) : | 240.78 |
MA(20) : | 233.03 |
| MA(100) : | 230.39 |
MA(250) : | 234.56 |
|
| MACD | MACD : | 3.8 |
Signal : | 2.8 |
| %K %D | K(14,3) : | 84.8 |
D(3) : | 83 |
| RSI | RSI(14): 68.2 |
|||
| 52-week | High : | 281.39 | Low : | 204.44 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ UTHR ] has closed below upper band by 19.0%. Bollinger Bands are 21.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 244.98 - 246.19 | 246.19 - 247.16 |
| Low: | 236.74 - 238.39 | 238.39 - 239.73 |
| Close: | 239.35 - 241.84 | 241.84 - 243.86 |
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Fri, 08 Dec 2023
Insider Sell Alert: EVP & GENERAL COUNSEL Paul Mahon Sells 6000 Shares of United ... - Yahoo Finance
Fri, 08 Dec 2023
United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly - Simply Wall St
Thu, 07 Dec 2023
United Therapeutics Named by Newsweek as One of America's Most Responsible Companies 2024 - Yahoo Finance
Wed, 29 Nov 2023
About UTHR – United Therapeutics Investor Relations - United Therapeutics Corporation
Fri, 24 Nov 2023
Why United Therapeutics (UTHR) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Thu, 16 Nov 2023
Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 47 (M) |
| Shares Float | 43 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 99.9 (%) |
| Shares Short | 1,130 (K) |
| Shares Short P.Month | 1,030 (K) |
| EPS | 18.13 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 121.58 |
| Profit Margin | 40.8 % |
| Operating Margin | 53.6 % |
| Return on Assets (ttm) | 10.8 % |
| Return on Equity (ttm) | 17.5 % |
| Qtrly Rev. Growth | 18.1 % |
| Gross Profit (p.s.) | 37.88 |
| Sales Per Share | 46.81 |
| EBITDA (p.s.) | 24.68 |
| Qtrly Earnings Growth | 9.6 % |
| Operating Cash Flow | 956 (M) |
| Levered Free Cash Flow | 593 (M) |
| PE Ratio | 13.32 |
| PEG Ratio | 1.2 |
| Price to Book value | 1.98 |
| Price to Sales | 5.16 |
| Price to Cash Flow | 11.88 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|